Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Jul;34(7):1585-90.
doi: 10.2337/dc11-0523. Epub 2011 May 24.

Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial

Kendra Vehik  1 , David Cuthbertson, Holly Ruhlig, Desmond A Schatz, Mark Peakman, Jeffrey P Krischer; DPT-1 and TrialNet Study Groups
Affiliations
Randomized Controlled Trial

Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial

Kendra Vehik et al. Diabetes Care. 2011 Jul.

Abstract

Objective: To evaluate the long-term intervention effects of oral insulin on the development of type 1 diabetes and to assess the rate of progression to type 1 diabetes before and after oral insulin treatment was stopped in the Diabetes Prevention Trial-Type 1 (DPT-1).

Research design and methods: The follow-up included subjects who participated in the early intervention of oral insulin (1994-2003) to prevent or delay type 1 diabetes. A telephone survey was conducted in 2009 to determine whether diabetes had been diagnosed and, if not, an oral glucose tolerance test (OGTT), hemoglobin A1c (HbA1c), and autoantibody levels were obtained on all subjects who agreed to participate.

Results: Of 372 subjects randomized, 97 developed type 1 diabetes before follow-up; 75% of the remaining 275 subjects were contacted. In the interim, 77 subjects had been diagnosed with type 1 diabetes and 54 of the remainder have had an OGTT; 10 of these were diagnosed with type 1 diabetes, subsequently. Among individuals meeting the original criteria for insulin autoantibodies (IAAs) (≥80 nU/mL), the overall benefit of oral insulin remained significant (P=0.05). However, the hazard rate in this group increased (from 6.4% [95% CI 4.5-9.1] to 10.0% [7.1-14.1]) after cessation of therapy, which approximated the rate of individuals treated with placebo (10.2% [7.1-14.6]).

Conclusions: Overall, the oral insulin treatment effect in individuals with confirmed IAA≥80 nU/mL appeared to be maintained with additional follow-up; however, once therapy stopped, the rate of developing diabetes in the oral insulin group increased to a rate similar to that in the placebo group.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of all subjects recruited into the original DPT-1 study and results of the follow-up study. IVGTT, intravenous glucose tolerance test; T1D, type 1 diabetes.
Figure 2
Figure 2
A: Time to type 1 diabetes for the entire DPT-1 population from 1994 to 2009. B: Time to type 1 diabetes for subjects with a baseline IAA level confirmed ≥80 nU/mL from 1994 to 2009. (A high-quality color representation of this figure is available in the online issue.)
Figure 3
Figure 3
Proportion of subjects with IAA levels confirmed ≥80 nU/mL who are diabetes-free by time of study and after study. A: Oral insulin treatment group (where “on treatment [Trt]” is defined as time receiving oral insulin). B: Placebo group (where “monitored” is defined as time receiving placebo and “not monitored” is defined as time no longer receiving placebo and monitored by study). (A high-quality color representation of this figure is available in the online issue.)
Figure 4
Figure 4
Proportion of subjects with IAA levels not confirmed ≥80 nU/mL who are diabetes-free by time of study and after study. A: Oral insulin treatment group (where “on treatment [Trt]” is defined as time receiving oral insulin). B: Placebo group (where “monitored” is defined as time receiving placebo and “not monitored” is defined as time no longer receiving placebo and monitored by study). (A high-quality color representation of this figure is available in the online issue.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care 2005;28:1068–1076 - PubMed
    1. Diabetes Prevention Trial–Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685–1691 - PubMed
    1. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88–92 - PubMed
    1. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97–104 - PubMed
    1. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006;13:143–157 - PMC - PubMed

Publication types